Curaleaf's Hostile Bid for Aurora Cannabis: Timeline, Terms and Analysis
This hub tracks multi-state operator Curaleaf's unsolicited, hostile takeover bid for Canadian licensed producer Aurora Cannabis. It covers Aurora's special committee, its repeated recommendation that shareholders reject Curaleaf's revised offer, and the strategic alternatives the committee says it is exploring to maximize shareholder value. It also explains how hostile bids work under Canadian takeover rules, what a board recommendation does and does not do, and what the deal could mean for the cannabis industry. Check the primary filings for exact offer terms. The page is updated as new developments are reported.

Executive summary
Curaleaf Holdings, the largest U.S. multi-state operator (MSO), is pursuing an unsolicited takeover of Canadian licensed producer Aurora Cannabis, and Aurora's board has rejected the revised offer. On October 15, 2026, Aurora said it reaffirmed its recommendation that shareholders reject Curaleaf's revised hostile bid. It also said a special committee of its board is actively exploring strategic alternatives to maximize value for shareholders, according to Cannabis Business Times.
The contest matters beyond the two companies. It is one of the first large attempts to join a Canadian, Nasdaq-listed medical and international cannabis platform with a U.S. plant-touching MSO. The deal sits where Canada's Cannabis Act, Canadian take-over bid rules, U.S. exchange listing standards, 280E tax treatment, and the federal rescheduling process meet.
This page is the running reference for the bid. It sets out what is confirmed, what the legal gates are, and which scenarios are plausible. The special committee's "strategic alternatives" language means Aurora is now openly testing the market for a competing transaction, a sale, or a standalone plan. That keeps every outcome live: a bump from Curaleaf, a white knight, a lapse of the offer, or a negotiated deal.
The public sources we reviewed for this foundation did not disclose every economic term of the revised offer. We have therefore flagged where readers should verify figures in the primary filings listed under Further reading. Dated updates will be appended below as the situation develops.
Why this matters
The bid tests whether U.S. MSO capital can acquire a Canadian federally legal producer before U.S. federal reform arrives, and it puts a premium price on international medical cannabis infrastructure.
Scale
Curaleaf reported roughly $1.3 billion in annual revenue in 2024, making it the largest U.S. operator by sales. It runs retail and cultivation across a large share of U.S. limited-license markets, including Florida, New York, New Jersey, Massachusetts, Pennsylvania, Illinois, Arizona and Ohio. Aurora is far smaller by revenue, roughly C$400 million a year in recent fiscal years. Its strategic value lies in Canadian licensed capacity, high-potency flower brands, and a medical export business serving Germany, the United Kingdom, Poland and Australia.
Stakeholders
- Aurora shareholders, a mix of Canadian institutions, U.S. retail holders on Nasdaq, and long-term holders who endured two share consolidations and billions of dollars of historical impairments.
- Curaleaf shareholders, who must weigh the cost and dilution of an acquisition against the strategic upside.
- International medical patients and distributors, who depend on Aurora's GMP-grade exports.
- Lenders and exchanges, whose rules decide whether a cross-border structure can close.
- Other acquirers, who may see the special committee process as an invitation.
Why the timing is unusual
The bid is happening while federal U.S. policy is in motion. The DEA's May 2024 NPRM proposed moving marijuana to Schedule III under 21 U.S.C. § 812, which would end the 26 U.S.C. § 280E tax bar on ordinary business deductions for plant-touching operators. The rescheduling process has been slowed by administrative law judge (ALJ) proceedings and political crosscurrents. Check the DEA and Federal Register for the current status. Curaleaf's board is, in effect, betting that the U.S. regulatory and exchange-access environment will improve enough to make a cross-border consolidation workable.
Background and history
The bid is the culmination of two diverging corporate paths: Aurora's Canadian-first, medical-export expansion and Curaleaf's U.S. limited-license roll-up.
2006-2014: Two companies, two regulatory worlds
Aurora was incorporated in Alberta in 2006 and entered Canada's federal medical cannabis program under the Marihuana for Medical Purposes Regulations around 2014. Curaleaf was founded in Massachusetts in 2010 and built its early business on state medical programs, with no federal pathway. That structural difference still defines the dispute. Aurora operates under federal licensing, and Curaleaf operates in a federally illegal U.S. market.
2018: Canadian legalization and the buying spree
Canada legalized adult-use cannabis on October 17, 2018, under the Cannabis Act (S.C. 2018, c. 16). Aurora spent heavily ahead of that date, acquiring CanniMed and MedReleaf, the latter in a deal valued at roughly C$3.2 billion. It listed on the NYSE in late 2018. The same year, Curaleaf listed on the Canadian Securities Exchange and closed its acquisition of Cura Partners (Select), then a landmark MSO deal.
2019-2020: Overbuilt capacity and the first reckoning
Canadian oversupply and weak retail rollout forced Aurora into large write-downs, facility closures and a 1-for-12 share consolidation in 2020. Curaleaf, by contrast, expanded: it entered Europe by acquiring EMMAC Life Sciences in the U.K., and later added Technical Cannabis and a German presence. Both firms were building European medical platforms, though from opposite capital structures.
2021: Curaleaf scales, Aurora shrinks
Curaleaf completed its acquisition of Grassroots, an approximately $875 million transaction at announcement, and listed on the Toronto Stock Exchange. Aurora restructured, cut costs and refocused on medical and international markets, a pivot that mattered later because German and other European import demand kept growing.
2023: Second consolidation and Nasdaq
Aurora completed a second 1-for-12 share consolidation in 2023 and pursued profitability on an adjusted EBITDA basis. It now trades on Nasdaq and the TSX under the symbol ACB. Nasdaq's listing posture matters because U.S. exchanges do not accommodate issuers with direct, U.S. plant-touching operations. That limitation shapes how any Curaleaf-Aurora combination could be financed and listed.
2024-2025: Rescheduling and a medical-export bull case
On May 21, 2024, the DEA's NPRM proposing Schedule III was published at 89 Fed. Reg. 44597. A hearing before an ALJ was set, then delayed. In late 2025 the White House signaled support for expediting rescheduling. Treat the status of that process as fluid and confirm current dates with the DEA docket. Meanwhile Germany's partial decriminalization and medical reforms boosted import demand, which is the segment where Aurora is strongest.
2026: The hostile bid
Curaleaf made an unsolicited offer for Aurora's shares and then revised it. On October 15, 2026, Aurora said it had reaffirmed its recommendation to reject the revised bid and that its special committee was exploring strategic alternatives. Updates below will track the offer's deposit deadlines, any amendments, and the outcome.
| Date | Event |
|---|---|
| 2006 | Aurora incorporated in Alberta |
| 2010 | Curaleaf founded in Massachusetts |
| Oct. 17, 2018 | Canada legalizes adult-use cannabis (Cannabis Act) |
| 2018 | Aurora buys MedReleaf and CanniMed; Curaleaf lists on CSE and buys Cura Partners |
| 2020 | Aurora's first 1-for-12 share consolidation |
| 2021 | Curaleaf buys Grassroots and lists on the TSX |
| 2023 | Aurora's second 1-for-12 consolidation |
| May 21, 2024 | DEA publishes Schedule III NPRM |
| Oct. 15, 2026 | Aurora reaffirms rejectionFrequently asked questionsWhat is the Curaleaf and Aurora Cannabis hostile bid?Curaleaf, a large U.S. multi-state cannabis operator, has made an unsolicited offer directly to Aurora Cannabis shareholders, without the agreement of Aurora's board. Aurora is a Canadian licensed producer with a major presence in Canadian and international medical cannabis. Because Aurora's board did not endorse the offer, it is considered hostile. Aurora's special committee has recommended that shareholders reject the revised bid. What is a hostile takeover bid?A hostile bid is an acquisition offer made directly to a target company's shareholders over the objection of its board of directors. The bidder typically launches a formal takeover bid, pitching shareholders on price and terms. The target board can respond by recommending rejection, seeking a higher competing offer, adopting defensive measures, or pursuing alternative transactions. Why did Aurora's board recommend rejecting Curaleaf's revised bid?Aurora's special committee reaffirmed its recommendation that shareholders reject the revised offer. It stated that it is exploring strategic alternatives to maximize shareholder value, which implies the committee does not view the bid as adequately reflecting Aurora's worth. Shareholders should read Aurora's directors' circular for the committee's detailed reasoning. What is a special committee and what does it do?A special committee is a group of independent directors formed to evaluate a significant transaction, such as a takeover proposal, free from management conflicts. It reviews offers, often with independent financial and legal advisers, and makes recommendations to the full board and shareholders. Aurora's special committee is also exploring strategic alternatives to the Curaleaf bid. What are 'strategic alternatives' for Aurora?Strategic alternatives is a broad term for options a company reviews to maximize shareholder value. These can include finding a rival bidder or merger partner, selling all or part of the business, a restructuring, or continuing as a standalone company with a revised plan. Aurora has not announced a specific outcome in the reporting cited here. Does the board's recommendation decide whether the bid succeeds?No. A board recommendation is influential but not binding. Shareholders decide by choosing whether to tender their shares into the offer. The bid must also meet its stated conditions, including any minimum tender requirement, and be completed under applicable securities, corporate and regulatory rules. How do Canadian takeover rules affect a hostile bid like this?Canadian takeover bid rules, administered by provincial securities regulators under National Instrument 62-104, generally require a minimum 105-day deposit period (unless the target board agrees to shorten it) and a minimum tender condition of more than 50% of outstanding shares held by independent holders. These rules give target boards time to seek alternatives. Exact timing depends on the bid documents. Who are Curaleaf and Aurora Cannabis?Curaleaf is one of the largest U.S. multi-state cannabis operators, with retail, cultivation and manufacturing operations and a presence in Europe. Aurora Cannabis is an Edmonton, Alberta-based licensed producer focused on Canadian adult-use and medical cannabis, plus international medical markets. Both are publicly traded companies. What should Aurora shareholders do now?Shareholders should review the offer documents and Aurora's directors' circular, note the deadlines, and consider independent financial and tax advice before tendering shares. Official company press releases and regulatory filings, such as those on SEDAR+, are the authoritative sources for terms, deadlines and any changes. This page is not investment advice. Why does this bid matter for the cannabis industry?A combination would link a major U.S. multi-state operator with a Canadian licensed producer, which is notable because cannabis remains federally illegal in the U.S. and regulated differently in Canada. The outcome may indicate how cross-border consolidation, valuations and capital-markets access evolve in the sector. curaleafaurora-cannabishostile-takeovercannabis-mergers-acquisitionscanadian-cannabis The CannIntel Daily The cannabis newsletter you forward to your team.Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free. No spam. Unsubscribe with one click. 21+ only. |